Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2018-10-22 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
关于投资设立全资子公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's investment to establish a wholly-owned subsidiary. It details the investment overview, the subsidiary's basic information, the purpose and risks of the investment, and includes independent directors' opinions. There are no financial statements or detailed financial performance data. The document is a corporate announcement about a capital investment and subsidiary formation, not a financial report or earnings release. It fits the category of Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes through the establishment of a new subsidiary.
2018-10-22 Chinese
重大投资公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company about multiple major investment projects, including descriptions of project scopes, investment amounts, economic benefits, and approval processes. It discusses strategic business expansions, capital expenditures, and funding sources, including a non-public stock issuance plan. The document is not a financial report like an annual or quarterly report, nor is it a transcript, audit, or legal proceeding. It is a comprehensive update on the company's capital investment activities and financing plans. Therefore, it fits best into the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a report publication notice.
2018-10-22 Chinese
控股股东、实际控制人、全体董事、高级管理人员关于公司非公开发行A股股票摊薄即期回报填补措施的承诺
Regulatory Filings Classification · 95% confidence The document is a formal commitment statement by the controlling shareholders, actual controllers, all directors, and senior management of Quantum Hi-Tech (China) Biological Co., Ltd. regarding measures to compensate for the dilution of immediate returns caused by a non-public issuance of A shares. It references regulatory guidelines and policies related to protecting investors' rights and ensuring fair practices in capital markets. The document is relatively short (1040 characters) and consists mainly of commitments and assurances rather than financial data or detailed report content. It does not contain financial statements, audit results, or detailed management discussion. It is not an announcement of voting results, nor a call transcript or earnings release. It is a regulatory compliance-related commitment document. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2018-10-22 Chinese
关于向关联方借款暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a related party loan transaction involving the company's subsidiary borrowing from a related party who is also a significant shareholder and vice chairman. It details the transaction terms, related party relationships, board approvals, and independent director opinions. The document is a formal disclosure of a related party transaction and does not contain financial statements or comprehensive financial data. It is not an annual or interim report, earnings release, or audit report. It is not a report publication announcement since it contains substantive transaction details. The content fits the category of a Regulatory Filing (RNS) as it is a regulatory disclosure about a related party transaction that does not fit other specific categories.
2018-10-22 Chinese
关于与尚华科创签订房屋租赁合同暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a related-party transaction involving a lease agreement between the company and an entity controlled by a company director. It details the terms of the lease, the related party relationship, the board approval process, and independent director opinions. There are no financial statements or comprehensive financial data presented. The document is a formal disclosure of a related-party transaction, typical of regulatory announcements required by stock exchanges. It is not an annual report, earnings release, or management report. It is not a voting result or a proxy statement. The document length is under 5,000 characters and is a detailed announcement rather than a report publication notice. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2018-10-22 Chinese
2018年前三季度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the first three quarters of 2018, providing estimated net profit figures and growth percentages compared to the previous year. It explicitly states that the forecast has not been audited and that detailed actual data will be disclosed in the company's third quarter report. The document is short (1068 characters) and serves as an announcement of expected financial results rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only.
2018-10-12 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.